Comparative Study of EDP-420 Versus Another Antibiotic in the Treatment of Community Acquired Pneumonia
| Status: | Completed |
|---|---|
| Conditions: | Pneumonia |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/2/2016 |
| Start Date: | December 2005 |
| End Date: | July 2007 |
| Contact: | Medical Director |
| Email: | clinical@enanta.com |
A Randomized, Double-Blinded, Parallel Group, Multicenter Study of EDP-420 Versus Telithromycin for the Treatment of Community Acquired Pneumonia
This study will compare the efficacy, safety and tolerability of EDP-420 versus another oral
antibiotic in the treatment of community acquired pneumonia
antibiotic in the treatment of community acquired pneumonia
Inclusion Criteria:
- Recent respiratory illness with signs and symptoms and chest X-ray consistent with
the diagnosis of community-acquired pneumonia.
- Suitable candidate for oral antibiotic therapy and able to swallow large capsules
intact
- If female, must be non-lactating and at no risk for pregnancy
Exclusion Criteria:
- Other infections
- Other pulmonary diseases requirement multiple antibacterial medications or long
duration of therapy
- History of hypersensitivity, allergic or adverse reactions to macrolide, ketolide,
azalide or streptogramins
- Evidence of uncontrolled clinically significant disease, malignancy, or other
abnormality
- Requirement of parenteral antimicrobial therapy for treatment of pneumonia
- Currently receiving or likely to receive any known inhibitors or inducers of
cytochrome P450 mediated drug metabolism
- Immunocompromised subjects
We found this trial at
1
site
Click here to add this to my saved trials